Neuren shares rise on record DAYBUE sales growth
Neuren Pharmaceuticals (ASX:NEU) reported net sales of its flagship Rett syndrome treatment, DAYBUE (trofinetide) in Q1.

Founder and CEO of Grafa, leading the company's vision to democratise financial data and empower investors with innovative tools.
Neuren Pharmaceuticals (ASX:NEU) reported net sales of its flagship Rett syndrome treatment, DAYBUE (trofinetide) in Q1.
Waratah Minerals (ASX:WTM) secured $48 million through a heavily oversubscribed share placement.
HESTA announced a substantial reduction in insurance fees, directly countering a wave of price increases across the broader market.
Keonne Rodriguez published a public appeal from federal prison asking Bitcoin holders to donate crypto to help his family manage mounting legal debt linked to the Samourai Wallet case.
US Foods Holding (NYSE:USFD) demonstrated resilient growth in the first quarter of fiscal 2026, successfully capturing market share in high-margin segments despite a softening broader economic backdrop.
Payoneer Global (NASDAQ:PAYO) delivered a robust first-quarter performance for 2026, marked by double-digit growth in its core business segments and an optimistic revision of its full-year financial outlook.
DNOW (NYSE:DNOW) delivered a quarter of significant strategic expansion and steady top-line performance, underscored by its entry into new high-margin automation sectors.
Kenvue (NYSE:KVUE) reported a strong start to the 2026 fiscal year, characterized by significant bottom-line growth and a marked improvement in operational efficiency.
EPAM Systems (NYSE:EPAM) reported a solid start to 2026, with financial results that reflect steady demand for its specialized AI and digital transformation services.
Canadian Natural Resources (NYSE:CNQ) delivered a strong first-quarter 2026 performance, marked by high operational reliability and significant capital returns to shareholders.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy